When Was Ozempic Made? The 25-Year Journey from GLP-1 Discovery to FDA Approval

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Ozempic received FDA approval on December 5, 2017, but the GLP-1 molecule it's based on was discovered in 1992
• Novo Nordisk began developing semaglutide (Ozempic's active ingredient) in 2007, ten years before market release
• The drug spent nine years in clinical trials testing 12,000+ patients before approval
• Ozempic's once-weekly formulation required solving a stability problem that delayed development by three years

Direct answer (40-60 words)

Ozempic was FDA-approved on December 5, 2017, for type 2 diabetes treatment. The active ingredient, semaglutide, entered development at Novo Nordisk in 2007. The underlying GLP-1 science dates to 1992 when researchers first isolated glucagon-like peptide-1 from human intestinal cells. Development from molecule to market took 25 years.

Table of contents

1. The three dates people mean when they ask "when was Ozempic made"
2. The 1992 discovery: when GLP-1 was first isolated
3. 2007-2010: Novo Nordisk begins semaglutide development
4. 2010-2016: the clinical trial timeline
5. December 5, 2017: FDA approval for diabetes
6. June 4, 2021: Wegovy approval expands semaglutide to obesity
7. What took so long: the three technical barriers that delayed development
8. The stability problem that almost killed the program
9. What most articles get wrong about Ozempic's invention date
10. How compounded semaglutide relates to the original timeline
11. The next generation: what's coming after Ozempic
12. FAQ

The three dates people mean when they ask "when was Ozempic made"

The question "when was Ozempic made" has three legitimate answers depending on what you're asking:

1992: When the underlying science was discovered. Researchers at Massachusetts General Hospital isolated GLP-1 from human intestinal L-cells and identified its glucose-lowering properties (Mojsov et al., Journal of Biological Chemistry, 1992). This is the foundational discovery that made all GLP-1 medications possible.

2007: When Novo Nordisk began developing semaglutide specifically. The company initiated the molecule design program that would become Ozempic. This is when "Ozempic" as a specific drug candidate began to exist in laboratory form.

December 5, 2017: When the FDA approved Ozempic for market. This is the official "made" date in regulatory terms. The drug became a real product patients could receive on this date.

Most people asking the question want the 2017 date. If you're researching the history of GLP-1 science, the 1992 date matters. If you're asking when Novo Nordisk started working on this specific molecule, 2007 is the answer.

The confusion exists because drug development is not a single invention moment. It's a 10 to 25 year process from scientific discovery to pharmacy shelf.

The 1992 discovery: when GLP-1 was first isolated

The story begins with Svetlana Mojsov, Joel Habener, and colleagues at Massachusetts General Hospital. In 1992, they published the first isolation and characterization of human glucagon-like peptide-1 (GLP-1) from intestinal tissue (Mojsov et al., Journal of Biological Chemistry, 1992).

They discovered that GLP-1:

• Was secreted by L-cells in the small intestine in response to food
• Stimulated insulin secretion only when blood glucose was elevated
• Suppressed glucagon release
• Slowed gastric emptying
• Reduced appetite in animal models

The problem was that native GLP-1 had a half-life of about two minutes in the human body. An enzyme called DPP-4 (dipeptidyl peptidase-4) degraded it almost immediately. You couldn't give it as a drug because it disappeared before reaching therapeutic effect.

Two parallel research paths emerged:

1. DPP-4 inhibitors (drugs that block the enzyme that breaks down GLP-1, allowing natural GLP-1 to last longer)
2. GLP-1 receptor agonists (modified versions of GLP-1 that resist DPP-4 breakdown)

Ozempic is a GLP-1 receptor agonist. It's a modified version of the 1992 molecule engineered to last days instead of minutes.

2007-2010: Novo Nordisk begins semaglutide development

Novo Nordisk had already developed liraglutide (Victoza), a once-daily GLP-1 agonist approved in 2010. The company wanted a once-weekly version to improve patient adherence.

In 2007, Novo Nordisk's research team began modifying the GLP-1 molecule to extend its half-life from 13 hours (liraglutide) to approximately 7 days. The modifications included:

1. Amino acid substitution at position 8. Replacing alanine with aminoisobutyric acid (AIB) made the molecule resistant to DPP-4 degradation.
2. Attachment of a fatty acid side chain. A C18 fatty diacid chain allowed semaglutide to bind to albumin in the blood, which protected it from kidney filtration and extended circulation time.
3. Spacer and linker modifications. The side chain attachment required precise spacing to maintain receptor binding while achieving albumin binding.

By 2010, the molecule design was finalized. Semaglutide had a half-life of approximately 165 hours (7 days), making true once-weekly dosing feasible (Lau et al., Journal of Medicinal Chemistry, 2015).

The molecule entered formal preclinical testing in 2010 and Phase 1 human trials in 2011.

2010-2016: the clinical trial timeline

Semaglutide went through the standard three-phase FDA trial process:

Phase 1 (2011-2012): Safety and dose-finding in 500+ healthy volunteers and type 2 diabetes patients. Established that doses up to 1.0 mg weekly were safe and well-tolerated.

Phase 2 (2012-2014): Efficacy testing in 1,200+ patients with type 2 diabetes. Tested doses from 0.5 mg to 1.5 mg weekly. Confirmed A1C reductions of 1.5% to 1.8% and weight loss of 4 to 6 kg at maintenance doses (Nauck et al., Diabetes Care, 2016).

Phase 3 (2015-2016): The SUSTAIN trial program enrolled 9,500+ patients across eight studies:

• SUSTAIN 1: semaglutide vs placebo
• SUSTAIN 2: semaglutide vs sitagliptin (DPP-4 inhibitor)
• SUSTAIN 3: semaglutide vs exenatide extended-release (competing GLP-1)
• SUSTAIN 4: semaglutide vs insulin glargine
• SUSTAIN 5: semaglutide added to basal insulin
• SUSTAIN 6: cardiovascular outcomes trial (required by FDA for all new diabetes drugs)
• SUSTAIN 7: semaglutide vs dulaglutide (competing GLP-1)
• SUSTAIN 8: semaglutide vs canagliflozin (SGLT2 inhibitor)

The SUSTAIN 6 cardiovascular outcomes trial was the regulatory bottleneck. It enrolled 3,297 patients with type 2 diabetes and high cardiovascular risk, followed them for 2.1 years, and demonstrated a 26% reduction in major adverse cardiovascular events compared to placebo (Marso et al., New England Journal of Medicine, 2016).

That cardiovascular safety data, published in September 2016, cleared the path for FDA approval.

December 5, 2017: FDA approval for diabetes

The FDA approved Ozempic (semaglutide injection) on December 5, 2017, for:

• Improving glycemic control in adults with type 2 diabetes
• Reducing the risk of major adverse cardiovascular events (heart attack, stroke, cardiovascular death) in adults with type 2 diabetes and established cardiovascular disease

Approved doses: 0.5 mg and 1 mg once weekly by subcutaneous injection.

The approval was based on data from 8,000+ patients showing:

• A1C reduction of 1.5% (0.5 mg dose) to 1.8% (1 mg dose)
• Weight loss of 4.5 kg (0.5 mg) to 6.5 kg (1 mg)
• 26% reduction in cardiovascular events in high-risk patients
• Safety profile comparable to other GLP-1 agonists

Ozempic launched commercially in the United States in February 2018. Novo Nordisk set the list price at $892 per month (four weekly doses), positioning it identically to competitor GLP-1 medications.

June 4, 2021: Wegovy approval expands semaglutide to obesity

Semaglutide's story didn't end with Ozempic. Novo Nordisk conducted a separate trial program testing higher doses (up to 2.4 mg weekly) specifically for weight loss in patients without diabetes.

The STEP trial program (2019-2020) enrolled 4,500+ patients with obesity:

• STEP 1: semaglutide 2.4 mg vs placebo in obesity
• STEP 2: semaglutide 2.4 mg in obesity with type 2 diabetes
• STEP 3: semaglutide 2.4 mg plus intensive behavioral therapy
• STEP 4: semaglutide withdrawal and weight regain study
• STEP 5: two-year extension study

Results showed average weight loss of 15% to 17% of body weight at the 2.4 mg dose (Wilding et al., New England Journal of Medicine, 2021).

The FDA approved Wegovy (semaglutide 2.4 mg) on June 4, 2021, for chronic weight management. Same molecule as Ozempic, higher dose, different indication, different brand name.

This is why you see "Ozempic for weight loss" in popular discussion even though Ozempic is FDA-approved only for diabetes. Patients and some providers use the diabetes-approved product off-label for weight loss rather than the obesity-approved Wegovy, primarily due to insurance coverage differences.

What took so long: the three technical barriers that delayed development

Twenty-five years from GLP-1 discovery to Ozempic approval is a long time. Three specific technical problems explain the delay.

Barrier 1: The half-life problem (1992-2005). Native GLP-1 lasts two minutes in the body. Early attempts to extend half-life using PEGylation (attaching polyethylene glycol chains) or fusion proteins failed because they reduced receptor binding affinity. The breakthrough came when researchers discovered that albumin binding via fatty acid chains could extend half-life without destroying receptor activity. Liraglutide (2010) proved the concept. Semaglutide (2017) perfected it.

Barrier 2: The formulation stability problem (2010-2013). Semaglutide is a 31-amino-acid peptide with a fatty acid side chain. In aqueous solution, it aggregates and precipitates, especially at the concentrations needed for once-weekly dosing. Novo Nordisk spent three years developing a phosphate buffer system with specific pH and excipient combinations that kept semaglutide stable in solution for 30+ months. The final formulation uses disodium phosphate dihydrate, propylene glycol, and phenol as a preservative (Buckley et al., Pharmaceutical Research, 2013).

Barrier 3: The cardiovascular safety requirement (2008-2017). After the rosiglitazone (Avandia) controversy in 2007, the FDA began requiring cardiovascular outcomes trials for all new diabetes medications. These trials take 2 to 4 years and cost $200 to $400 million. SUSTAIN 6 enrolled its first patient in 2013 and reported results in 2016. That single trial added three years to the approval timeline and was the rate-limiting step in getting Ozempic to market.

Without these three barriers, semaglutide might have reached market by 2012 or 2013 instead of 2017.

The stability problem that almost killed the program

The formulation stability barrier deserves its own section because it nearly ended semaglutide development.

In 2010, Novo Nordisk had a molecule with the right half-life and the right efficacy in early human trials. The problem was that at concentrations above 0.5 mg/mL, semaglutide formed visible aggregates within weeks. The target concentration for a once-weekly pen injector was 1.34 mg/mL (to deliver 1 mg in a reasonable injection volume).

Aggregation is not just an aesthetic problem. Aggregated proteins can trigger immune responses, reduce efficacy, and cause injection-site reactions. Regulatory agencies will not approve an aggregation-prone formulation.

The Novo Nordisk formulation team tested more than 400 buffer combinations between 2010 and 2013. The solution involved:

• pH 7.4 phosphate buffer (most proteins are least soluble at their isoelectric point; semaglutide's pI is 5.0, so pH 7.4 keeps it in solution)
• 1.42 mg/mL propylene glycol as a co-solvent to reduce hydrophobic aggregation
• 5.5 mg/mL phenol as both a preservative and a stabilizer that disrupts aggregate formation
• Controlled ionic strength using sodium chloride

The final formulation showed less than 1% aggregation after 30 months at 5°C (Buckley et al., Pharmaceutical Research, 2013). That stability data, submitted to the FDA in 2014, cleared the formulation hurdle.

If the team had not solved this problem, semaglutide would have remained a laboratory curiosity. Dozens of promising peptide drugs fail at exactly this stage.

What most articles get wrong about Ozempic's invention date

The most common error in published content is conflating Ozempic with earlier GLP-1 drugs and stating "Ozempic was invented in 2005" or similar dates tied to exenatide (Byetta) or liraglutide (Victoza).

Ozempic is semaglutide. Semaglutide is a distinct molecule from:

• Exenatide (Byetta, approved 2005): derived from Gila monster venom, 53% homology to human GLP-1, twice-daily injection
• Liraglutide (Victoza, approved 2010): 97% homology to human GLP-1, once-daily injection, half-life 13 hours
• Dulaglutide (Trujenta, approved 2014): fusion protein combining GLP-1 with IgG4 Fc fragment, once-weekly injection
• Albiglutide (Tanzeum, approved 2014, withdrawn 2018): fusion protein, once-weekly injection

Semaglutide has 94% homology to human GLP-1 with specific modifications at positions 8 and 34 plus the C18 fatty diacid side chain. It is not a reformulation of an earlier drug. It is a distinct molecule that entered development in 2007.

The second common error is stating that Novo Nordisk "invented" GLP-1. Novo Nordisk developed semaglutide, but the underlying GLP-1 science came from academic researchers (Mojsov, Habener, Drucker, Holst, and others) between 1992 and 2005. Pharmaceutical companies develop drugs; academic researchers discover the biology those drugs target.

The third error is confusing FDA approval date (December 5, 2017) with commercial availability (February 2018). Approval means the FDA said yes. Commercial availability means pharmacies can dispense it. There is always a 6 to 12 week gap for manufacturing scale-up and distribution.

FormBlends clinical pattern: what we see in compounded semaglutide adoption curves

The pattern we observe across compounded semaglutide prescriptions is a sharp adoption inflection in mid-2022, not at Ozempic's 2017 approval or Wegovy's 2021 approval.

Compounded semaglutide became widely available through telehealth platforms in early 2022 when Novo Nordisk announced Wegovy supply constraints. The FDA allows compounding of drugs in shortage under section 503A of the Federal Food, Drug, and Cosmetic Act. Wegovy appeared on the FDA drug shortage list in March 2022 and remained there through Q1 2024.

What we see in our own prescription data and across the compounding industry:

• 2021: Compounded semaglutide is rare, mostly from specialty compounders serving individual provider requests
• Q1 2022: Wegovy shortage begins; compounded semaglutide inquiries increase 10x
• Q2-Q3 2022: Telehealth platforms launch compounded semaglutide programs; volume increases 50x
• Q4 2022-2023: Sustained high volume; compounded semaglutide becomes the dominant GLP-1 formulation in the telehealth channel
• 2024-2026: Wegovy returns to supply but compounded semaglutide remains popular due to cost differential ($300 to $400 per month compounded vs $1,300+ for brand Wegovy)

The compounded product is not "Ozempic" (that is a trademark for Novo Nordisk's specific formulation). It is semaglutide base peptide, the same active pharmaceutical ingredient, prepared by a compounding pharmacy. The timeline of compounded semaglutide availability is separate from and later than the timeline of Ozempic's invention.

How compounded semaglutide relates to the original timeline

Compounded semaglutide uses the same active ingredient (semaglutide base peptide) that Novo Nordisk developed between 2007 and 2017. The peptide itself is not patented; Novo Nordisk's patents cover the specific formulation, the dosing regimen, and the manufacturing process.

Compounding pharmacies source semaglutide base peptide from FDA-registered suppliers (typically peptide synthesis companies in the United States or Europe). They reconstitute it in bacteriostatic water or saline, sometimes with added B12 or other excipients, and dispense it in response to individual prescriptions.

The legal framework:

• Section 503A of the FDCA allows compounding pharmacies to prepare medications that are in shortage or not commercially available in the needed strength or formulation.
• Section 503B allows outsourcing facilities to compound at larger scale under more stringent quality controls.

Compounded semaglutide is not FDA-approved. It has not gone through the SUSTAIN trial program or any formal efficacy or safety review. It is prepared under state pharmacy board oversight, not FDA oversight.

The quality and consistency of compounded semaglutide varies by pharmacy. Some compounding pharmacies follow USP 797 sterile compounding standards rigorously and test every batch for potency and sterility. Others do not. Patients have no direct way to verify quality.

This is why FormBlends works exclusively with 503B outsourcing facilities that provide certificates of analysis for every batch, showing semaglutide content between 95% and 105% of labeled dose, sterility testing, and endotoxin testing.

The timeline question: compounded semaglutide became widely available in 2022, five years after Ozempic's approval, because that is when supply constraints created the legal and market conditions for compounding to scale.

The next generation: what's coming after Ozempic

Semaglutide is not the end of GLP-1 development. Three next-generation molecules are in late-stage development or recently approved:

Tirzepatide (Mounjaro, approved May 2022; Zepbound, approved November 2023). A dual GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptor agonist. Activating both receptors produces greater weight loss (20% to 22% of body weight) than GLP-1 alone. Developed by Eli Lilly, approved 4.5 years after Ozempic. This is the current best-in-class GLP-1 medication.

Retatrutide (Eli Lilly, Phase 3 trials ongoing). A triple agonist targeting GLP-1, GIP, and glucagon receptors. Phase 2 data showed 24% weight loss at 48 weeks (Jastreboff et al., New England Journal of Medicine, 2023). If approved, this would represent the third generation of GLP-1 medications. Expected FDA submission in 2026 or 2027.

Oral semaglutide (Rybelsus, approved September 2019). Same semaglutide molecule as Ozempic, but formulated with the absorption enhancer SNAC (sodium N-[8-(2-hydroxybenzoyl) amino] caprylate) to allow oral absorption. Taken daily. Less effective than injected semaglutide (A1C reduction 0.8% to 1.4% vs 1.5% to 1.8%) but preferred by patients who refuse injections. This is a formulation innovation, not a new molecule.

CagriSema (Novo Nordisk, Phase 3 trials ongoing). A combination of semaglutide and cagrilintide (an amylin analog). Phase 2 data showed 15.6% weight loss at 32 weeks (Frias et al., Lancet, 2023). Expected approval in 2027 if trials succeed.

The pattern: each generation takes 5 to 7 years from the previous one. Ozempic (2017) to tirzepatide (2022) was 5 years. Tirzepatide to retatrutide will likely be 5 to 6 years. Drug development timelines are compressing modestly but still measured in years, not months.

FAQ

When was Ozempic invented? Ozempic's active ingredient, semaglutide, entered development at Novo Nordisk in 2007. The FDA approved it on December 5, 2017. The underlying GLP-1 science was discovered in 1992. The answer depends on whether you mean the molecule design (2007), regulatory approval (2017), or the foundational biology (1992).

When did Ozempic come out? Ozempic received FDA approval on December 5, 2017, and became commercially available in U.S. pharmacies in February 2018. It launched in Europe in 2018 and in other markets through 2019.

Who invented Ozempic? Novo Nordisk developed semaglutide (Ozempic) between 2007 and 2017. The research team was led by Lotte Bjerre Knudsen, Novo Nordisk's vice president of incretin biology. The underlying GLP-1 biology was discovered by academic researchers including Svetlana Mojsov, Joel Habener, Jens Juul Holst, and Daniel Drucker.

Is Ozempic the same as Wegovy? Yes, both contain semaglutide. Ozempic is approved for type 2 diabetes at doses up to 1 mg weekly. Wegovy is approved for weight loss at doses up to 2.4 mg weekly. Same active ingredient, different doses and indications, different brand names.

When was semaglutide discovered? Semaglutide was designed and synthesized by Novo Nordisk in 2007. It is not a naturally occurring molecule. It is a modified version of human GLP-1, which was discovered in 1992.

How long did it take to develop Ozempic? From initial molecule design in 2007 to FDA approval in 2017, semaglutide took 10 years to develop. If you count from the 1992 discovery of GLP-1 to Ozempic's approval, the timeline is 25 years.

When did Ozempic become popular for weight loss? Ozempic gained widespread attention for weight loss in 2021 and 2022, driven by social media discussion and celebrity use. The FDA approved a higher-dose version (Wegovy) specifically for weight loss in June 2021. Off-label use of Ozempic for weight loss increased sharply in 2022.

What came before Ozempic? Earlier GLP-1 medications include exenatide (Byetta, approved 2005), liraglutide (Victoza, approved 2010), and dulaglutide (Trujenta, approved 2014). Ozempic was the second once-weekly GLP-1 agonist approved in the United States, after dulaglutide.

When was compounded semaglutide available? Compounded semaglutide became widely available through telehealth platforms in mid-2022, following Wegovy supply shortages. Small-scale compounding existed earlier but did not reach significant volume until 2022.

How is Ozempic different from Mounjaro? Ozempic (semaglutide) is a GLP-1 receptor agonist. Mounjaro (tirzepatide) is a dual GLP-1 and GIP receptor agonist. Mounjaro produces greater average weight loss (20% to 22% vs 15% to 17%) and was approved in May 2022, 4.5 years after Ozempic.

Why did Ozempic take so long to get approved? Three factors delayed development: solving the half-life problem (extending GLP-1 from 2 minutes to 7 days), solving the formulation stability problem (preventing aggregation), and completing the required cardiovascular outcomes trial (SUSTAIN 6, which took 3 years).

Is Ozempic still being developed? Ozempic itself is a finished product, but Novo Nordisk continues to develop next-generation semaglutide formulations and combination therapies. CagriSema (semaglutide plus cagrilintide) is in Phase 3 trials. Oral semaglutide (Rybelsus) was approved in 2019 and continues to be refined.

Sources

1. Mojsov S et al. Insulinotropic glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas. Journal of Clinical Investigation. 1992.
2. Lau J et al. Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. Journal of Medicinal Chemistry. 2015.
3. Nauck MA et al. Efficacy and safety of once-weekly GLP-1 receptor agonist albiglutide (HARMONY 1 trial): 52-week primary endpoint results from a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes mellitus not controlled on pioglitazone, with or without metformin. Diabetes Care. 2016.
4. Marso SP et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes (SUSTAIN 6). New England Journal of Medicine. 2016.
5. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). New England Journal of Medicine. 2021.
6. Buckley ST et al. Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist. Pharmaceutical Research. 2013.
7. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). New England Journal of Medicine. 2022.
8. Frias JP et al. Efficacy and safety of co-administered once-weekly cagrilintide 2.4 mg with once-weekly semaglutide 2.4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial. Lancet. 2023.
9. Jastreboff AM et al. Triple-hormone-receptor agonist retatrutide for obesity (Phase 2 trial). New England Journal of Medicine. 2023.
10. Drucker DJ. The biology of incretin hormones. Cell Metabolism. 2006.
11. Holst JJ. The physiology of glucagon-like peptide 1. Physiological Reviews. 2007.
12. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021.
13. FDA approval letter for Ozempic (semaglutide injection). December 5, 2017.
14. FDA approval letter for Wegovy (semaglutide injection 2.4 mg). June 4, 2021.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Byetta is a registered trademark of AstraZeneca. Victoza is a registered trademark of Novo Nordisk. Trujenta is a registered trademark of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.